AAM Stares Into The Biosimilar Void

Report Offers ‘Sobering Wake-Up Call’ For Stakeholders

 
• By Dave Wallace
  
The US ‘Biosimilar Void’ means that only 12 of 118 biologics losing exclusivity over the next ten years have biosimilars in the pipeline (Shutterstock)

More from AAM

More from Drug Pricing